Last updated: November 11, 2026
The combination of calcium carbonate, famotidine, and magnesium hydroxide is marketed primarily as the OTC heartburn product Pepcid Complete. Its commercial proposition combines rapid acid neutralization from calcium carbonate and magnesium hydroxide with longer-duration acid suppression from famotidine. The product operates in a mature, heavily competitive OTC category with low regulatory barriers, limited product-level financial disclosure, and no meaningful biologic or biosimilar exposure.
What product contains calcium carbonate, famotidine, and magnesium hydroxide?
Pepcid Complete is the principal U.S. product associated with the three-ingredient combination. Each chewable tablet contains:
| Active ingredient |
Amount per tablet |
Commercial role |
| Famotidine |
10 mg |
H2-receptor antagonist that reduces gastric acid production |
| Calcium carbonate |
800 mg |
Rapid acid neutralizer |
| Magnesium hydroxide |
165 mg |
Rapid acid neutralizer and calcium carbonate balancing agent |
The product is indicated for relief of heartburn associated with acid indigestion and for prevention of heartburn when taken before a meal or beverage expected to cause symptoms. The formulation is administered as a chewable tablet, which supports consumer convenience and avoids the need for water.[1]
Pepcid Complete differs from standard Pepcid products that contain famotidine alone. It also differs from traditional antacids such as Tums, Rolaids, and Maalox, which provide neutralization without an H2-receptor antagonist.
How does the calcium carbonate-famotidine-magnesium hydroxide combination work?
The formulation uses two pharmacologic mechanisms.
Calcium carbonate and magnesium hydroxide neutralize acid already present in the stomach. This produces relatively rapid symptom relief. Famotidine blocks histamine H2 receptors on gastric parietal cells and reduces subsequent acid secretion. Its effect generally lasts longer than the immediate neutralizing action of the antacid ingredients.
The combination therefore competes across two consumer needs:
- Immediate relief from existing heartburn.
- Longer control of acid production after dosing.
The formulation also balances certain tolerability characteristics. Calcium carbonate can contribute to constipation, while magnesium hydroxide can contribute to loose stools. Combining the two antacids can reduce the commercial and tolerability disadvantages associated with using either salt alone, although gastrointestinal effects remain possible.[1]
What is the FDA regulatory status of Pepcid Complete?
Pepcid Complete is an OTC drug product with labeling reviewed under the FDA’s nonprescription drug framework. The active ingredients fall within long-established OTC regulatory categories covering H2-receptor antagonists and antacid products.[2][3]
| Regulatory element |
Status |
| Dosage form |
Chewable tablet |
| Route |
Oral |
| Prescription requirement |
No |
| Primary U.S. indication |
Heartburn relief and prevention |
| H2 blocker |
Famotidine |
| Antacid ingredients |
Calcium carbonate and magnesium hydroxide |
| Biologic status |
Not applicable |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
OTC equivalent and private-label competition |
| Product sponsor |
Kenvue’s consumer-health portfolio following the Johnson & Johnson separation |
The product’s commercial protection does not depend on biologic exclusivity, Hatch-Waxman exclusivity, or complex manufacturing controls. Its regulatory position is closer to a branded OTC franchise than to a newly approved prescription drug.
What is the Orange Book status of calcium carbonate, famotidine, and magnesium hydroxide?
The active ingredients have long histories of OTC use, and the commercial market is not protected by a current composition-of-matter patent covering the three ingredients. The combination is also not dependent on a novel molecular entity.
The Orange Book is less important for this product than it is for a conventional prescription drug because:
- The product is sold over the counter.
- The active ingredients are established.
- Competing antacid and famotidine products can be developed without reproducing a proprietary active pharmaceutical ingredient.
- The principal barriers are branding, retail placement, consumer recognition, and formulation execution.
Any historical patents covering Pepcid or related famotidine formulations would generally have expired after decades of commercial use. The remaining commercial rights are more likely to involve trademarks, packaging, trade dress, private-label supply agreements, and retail distribution arrangements than enforceable active-ingredient patents.[4]
What patents protect Pepcid Complete and its formulation?
The practical patent position is weak relative to recently launched prescription products.
| Protection category |
Current commercial relevance |
| Famotidine composition patents |
Expired |
| Calcium carbonate composition patents |
Not applicable to the mature ingredient |
| Magnesium hydroxide composition patents |
Not applicable to the mature ingredient |
| Combination patents |
Historical protection has expired or has limited market effect |
| Chewable-tablet formulation patents |
Limited, with potential relevance only if a specific formulation remains enforceable |
| Manufacturing patents |
Low strategic value because comparable manufacturing methods are widely available |
| Trademarks and brand assets |
High commercial relevance |
| Packaging and trade dress |
Moderate commercial relevance |
| Retail and distribution contracts |
High commercial relevance in OTC channels |
The most defensible assets are therefore brand-based. Pepcid has decades of consumer awareness, physician familiarity, and shelf recognition. Those advantages can preserve price premiums even when private-label products contain the same active ingredients.
When does Pepcid Complete lose exclusivity?
Pepcid Complete does not have a single future loss-of-exclusivity date comparable to a patented prescription medicine. Its core ingredient exclusivity has already ended.
The product’s effective commercial exclusivity was eroded in stages:
| Period |
Market development |
| 1980s-1990s |
Famotidine prescription franchise established |
| 1990s-2000s |
Famotidine and antacid combinations expanded into consumer markets |
| 2000s onward |
Generic famotidine and competing antacid brands became widely available |
| Current market |
Brand competition is based on recognition, formulation, price, and distribution |
Generic and private-label manufacturers do not need to wait for a future patent expiry to compete with the active ingredients. The primary launch question is whether a product complies with applicable OTC rules and labeling requirements.
What generic entry risks exist for Pepcid Complete?
Generic entry risk is high because the combination uses inexpensive, widely available ingredients and a simple oral dosage form.
Potential competitors include:
- Store-brand chewable heartburn products.
- Private-label products supplied by contract manufacturers.
- Famotidine-only products used alongside calcium carbonate or magnesium hydroxide.
- Chewable antacid products containing different H2-blocker or antacid combinations.
- Liquid and tablet antacid products that compete for the same consumer occasion.
A direct private-label equivalent can pressure price and retailer margins. An indirect substitute can reduce demand without matching the exact ingredient combination. For example, a consumer may choose famotidine tablets for preventive use and a separate antacid for breakthrough symptoms.
The principal defenses are brand loyalty, advertising, product availability, retailer relationships, and a familiar dosing proposition. Patent litigation is unlikely to be the central competitive tool.
What is the competitive landscape for this heartburn combination?
Pepcid Complete competes across several overlapping OTC segments.
| Competitor group |
Representative products |
Competitive advantage |
| Famotidine products |
Pepcid AC, store-brand famotidine |
Longer acid suppression and simple dosing |
| Calcium carbonate products |
Tums and private-label calcium carbonate |
Low price and rapid relief |
| Calcium/magnesium antacids |
Rolaids and related products |
Familiar combination antacid positioning |
| Aluminum/magnesium products |
Maalox and store brands |
Liquid and chewable formulation options |
| Proton-pump inhibitors |
Prilosec OTC, Nexium 24HR, Prevacid 24HR |
Longer acid suppression for frequent symptoms |
| Combination products |
Pepcid Complete and private-label equivalents |
Immediate relief plus acid suppression |
Pepcid Complete is positioned between basic antacids and proton-pump inhibitors. It is faster acting than a proton-pump inhibitor for immediate symptoms but generally less suitable for consumers seeking continuous control of frequent reflux.
Its main market risk is category substitution. Consumers with occasional symptoms may trade down to low-cost antacids. Consumers with recurring symptoms may trade up to proton-pump inhibitors or seek physician-directed treatment.
How strong is the patent estate for calcium carbonate, famotidine, and magnesium hydroxide?
The patent estate is commercially weak and legally mature.
Composition-of-matter protection
No meaningful current composition-of-matter barrier protects the three active ingredients. Famotidine was discovered and commercialized decades ago. Calcium carbonate and magnesium hydroxide are established antacid substances with extensive prior use.
Formulation protection
A particular chewable formulation may have had historical protection involving excipient selection, taste masking, tablet hardness, dissolution, or manufacturing parameters. Those rights are less valuable when competing manufacturers can design around them using conventional excipients and different process conditions.
Method-of-use protection
Method-of-use patents have limited relevance in an OTC market where heartburn relief and prevention are established uses. Broad claims covering treatment of acid indigestion or heartburn face substantial prior-art and obviousness challenges.
Manufacturing and supply-chain protection
Manufacturing is not a major IP barrier. The active ingredients are inexpensive, stable, and available from multiple suppliers. The more material operational risks involve:
- Ingredient qualification.
- Tablet taste and mouthfeel.
- Product uniformity.
- Packaging stability.
- Retailer service levels.
- FDA compliance and quality systems.
Which companies are challenging Pepcid Complete?
Competition is fragmented rather than concentrated in a single patent challenger.
Kenvue competes with:
- Retailer-owned private-label manufacturers.
- Perrigo and other OTC contract manufacturers.
- Haleon through antacid brands such as Tums, Rolaids, and related products.
- Bayer and other suppliers of antacid products.
- AstraZeneca’s legacy Nexium OTC franchise and other proton-pump inhibitor suppliers.
- Generic manufacturers selling famotidine-only products.
The market does not require a formal Paragraph IV challenge for entry. A company can enter with a compliant OTC product without litigating a patent if no enforceable listed patent blocks the formulation.
Are there Paragraph IV challenges or patent litigation?
Paragraph IV litigation is not the principal entry mechanism for this product. The combination is a mature OTC formulation with expired foundational ingredient protection and broad competitive substitution.
No major current litigation dynamic comparable to a branded prescription-drug patent dispute defines the market. Potential disputes would more likely involve:
- Trademark infringement.
- False advertising.
- Packaging or trade-dress similarity.
- Retail exclusivity.
- Product-quality or labeling allegations.
- Contract disputes involving private-label supply.
The absence of a major patent dispute reduces legal uncertainty for generic and store-brand competitors.
What licensing deals affect Pepcid Complete?
The product’s original development and commercialization history involved Johnson & Johnson and its consumer-health operations. Following the separation of Kenvue from Johnson & Johnson, the relevant commercial assets moved into Kenvue’s consumer-health portfolio.
Public disclosures do not provide a separate Pepcid Complete royalty stream or product-level licensing revenue. The economic value is therefore captured through the broader consumer-health business rather than reported as a standalone licensing asset.[5]
What is the financial trajectory for Pepcid Complete?
Kenvue does not publicly report Pepcid Complete revenue as a separate line item. Product-level sales, gross margin, advertising spending, and operating profit are not disclosed in the company’s principal public filings.
The financial trajectory is best assessed through market structure:
| Financial driver |
Expected effect |
| Mature active ingredients |
Low cost of goods |
| Strong brand recognition |
Supports price premium |
| Private-label competition |
Compresses pricing |
| OTC shelf placement |
Supports volume and visibility |
| Consumer advertising |
Required to defend brand share |
| Famotidine demand |
Supports preventive heartburn use |
| PPI competition |
Limits long-term category expansion |
| Retailer bargaining power |
Pressures trade spending and margins |
| Product simplicity |
Limits manufacturing complexity |
| Regulatory maturity |
Reduces development spending |
The product is likely a cash-generative mature brand rather than a high-growth pharmaceutical asset. Revenue growth depends more on pricing, distribution, advertising effectiveness, and category demand than on patent-protected market expansion.
Kenvue’s broader financial performance is influenced by multiple brands and categories, including skin health, self-care, and essential health products. Pepcid Complete’s standalone contribution cannot be isolated from public company reporting.[5]
What generic launch scenarios exist?
Scenario 1: Store-brand direct equivalents
Retailers launch products containing the same three active ingredients in a chewable tablet. This is the clearest threat to branded pricing and can occur with limited development risk.
Scenario 2: Famotidine-led substitution
Consumers shift to low-cost famotidine tablets and use separate antacids as needed. This reduces the value of the integrated combination.
Scenario 3: Antacid-led substitution
Consumers choose calcium carbonate or calcium/magnesium products because they are cheaper and familiar. This scenario is strongest for occasional heartburn.
Scenario 4: Proton-pump inhibitor migration
Consumers with frequent symptoms move to OTC proton-pump inhibitors. The shift can reduce repeat purchases of Pepcid Complete even when total reflux-treatment spending rises.
Scenario 5: Brand resilience
Kenvue maintains share through advertising, wide distribution, recognizable packaging, and the product’s simple immediate-plus-longer-duration proposition. In this scenario, generic products grow in unit volume but do not eliminate the brand’s premium segment.
How does Pepcid Complete compare with Pepcid AC and Tums?
| Attribute |
Pepcid Complete |
Pepcid AC |
Tums |
| Famotidine |
Yes |
Yes |
No |
| Calcium carbonate |
Yes |
No |
Yes |
| Magnesium hydroxide |
Yes |
No |
Usually no |
| Immediate neutralization |
Yes |
Limited |
Yes |
| Longer acid suppression |
Yes |
Yes |
No |
| Main use case |
Immediate and sustained relief |
Prevention and longer control |
Rapid occasional relief |
| Patent risk |
Low |
Low |
Low |
| Price pressure |
High |
High |
Very high |
| Main commercial asset |
Brand and combination convenience |
Famotidine brand |
Familiarity and low price |
What geographic markets matter?
The United States is the most commercially relevant market for Pepcid Complete because of the brand’s U.S. consumer-health presence and the availability of OTC famotidine products.
Outside the United States, regulatory classifications, brand ownership, permitted dosages, and product names vary. Some markets regulate H2 antagonists more restrictively, while others permit broader OTC access. International expansion is therefore limited by local registration and distribution economics rather than patent exclusivity.
The geographic opportunity is strongest where:
- Heartburn treatment is predominantly OTC.
- Retail pharmacy and mass-market channels are developed.
- Consumers recognize the Pepcid brand.
- Combination antacid products are accepted by regulators.
- Private-label competition is less entrenched.
Key Takeaways
- Pepcid Complete is the principal commercial product containing famotidine, calcium carbonate, and magnesium hydroxide.
- The formulation combines rapid acid neutralization with longer-duration H2-receptor blockade.
- Foundational ingredient and combination protection is mature; no meaningful composition-of-matter barrier remains.
- The product has high generic and private-label entry risk.
- Paragraph IV litigation is not the main competitive pathway.
- Brand recognition, shelf placement, retailer access, and advertising are more important than patents.
- Kenvue does not separately disclose Pepcid Complete revenue or profit.
- The product is best viewed as a mature OTC cash-flow brand with modest growth potential and persistent pricing pressure.
- The main substitutes are famotidine-only products, calcium carbonate antacids, calcium/magnesium antacids, and proton-pump inhibitors.
- Manufacturing is relatively straightforward, so supply-chain execution and consumer marketing are more important than proprietary production technology.
FAQs About Calcium Carbonate, Famotidine, and Magnesium Hydroxide
Is Pepcid Complete the same as Pepcid AC?
No. Pepcid Complete contains famotidine plus calcium carbonate and magnesium hydroxide. Pepcid AC generally contains famotidine without the two antacid ingredients.
Can a generic company copy Pepcid Complete?
A manufacturer can compete with a comparable OTC combination if its product complies with FDA requirements and does not infringe enforceable brand, formulation, or packaging rights. The active ingredients themselves are not a meaningful barrier.
Does Pepcid Complete have biosimilar competition?
No. Pepcid Complete is a small-molecule OTC drug product, not a biologic. Biosimilar regulation does not apply.
Which ingredient provides the fastest relief?
Calcium carbonate and magnesium hydroxide provide the principal rapid acid-neutralizing effect. Famotidine contributes longer-duration acid suppression rather than the primary immediate neutralization.
Is the product financially exposed to proton-pump inhibitors?
Yes. Proton-pump inhibitors compete for consumers with frequent or recurring heartburn. Their use can reduce repeat demand for combination H2-blocker and antacid products, although Pepcid Complete retains a position for consumers seeking faster relief.
References
- U.S. National Library of Medicine. (2024). Pepcid Complete chewable tablets: Drug label. DailyMed.
- U.S. Food and Drug Administration. (2020). Over-the-counter monograph M001: Antacid products for over-the-counter human use.
- U.S. Food and Drug Administration. (2020). Over-the-counter monograph M005: Labeling for over-the-counter human drug products.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
- Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
